The inability of tumor lines to produce PGE2 renders them highly susceptible to cDC1-dependent CD8+ T-cell-mediated immune control [19], and researchers have exploited preclinical Ptgs1/Ptgs2-/- tumor models to characterize the mechanisms controlling cDC1 accumulation. This evidence concerns the gene CD8A and neoplasm.